Grepafloxacin: microbiological properties

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Approach to diagnosis of infective endocarditis

P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys

The changing epidemiology of severe infections in the ICU

Herpes zoster in non-hospitalized children

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

Atypical respiratory pathogens

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Hydatid disease Clinical Microbiology and Infection

Link between intracellular pathogens and cardiovascular diseases

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Serotypes, biotypes and antimicrobial susceptibilities of Haemophilus influenzae isolated from invasive disease in children in Casablanca N. Moustaoui,

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

Inga Odenholt, Elisabeth Löwdin, Otto Cars

The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci Keith Klugman, Fred Goldstein,

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Sofie Arens, Jan Verhaegen, Ludo Verbist

Mechanisms of quinolone resistance in clinical isolates of Enterobacter cloacae Apostolos Georgopoulos, Robert Schein, Astrid Buxbaum, Susan Tzotzos,

Training for the infectious diseases speciality in Norway

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach,

Pharmacodynamic properties of HMR 3004, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time.

Cephalosporins: a pharmacological update

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Sepsis and neutropenia induced by clozapine

Uncommon opportunistic fungi: new nosocomial threats

Elements of design: the knowledge on which we build

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

André Bryskier Clinical Microbiology and Infection

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens* M. Kanellopoulou, A. Makri,

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

A. Bryskier Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Role of communicable disease control measures in affecting the spread of resistant pneumococci: the Swedish model Karl Ekdahl, Otto Cars Clinical Microbiology.

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Community-acquired pneumonia: epidemiologic and clinical consideration

Grepafloxacin: pharmacokinetics and tissue penetration

Reducing antibiotic use in influenza: challenges and rewards

Fibronectin concentrations in catheter sepsis

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Definition of the Clinical Antibacterial Spectrum of Activity

Ethan Rubinstein, Itzhak Levy Clinical Microbiology and Infection

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Empiric therapy of bacterial infections in severe neutropenia

Overview of cefixime use in community-acquired infections

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

Sanford Chodosh Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

Modification of prescribers’ behavior: the Icelandic approach

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

Fernando Baquero, John F

Localized Mycobacterium avium complex infection in a patient on HAART

The future of diagnostic bacteriology

Presentation transcript:

Grepafloxacin: microbiological properties Michael S. Marriott Clinical Microbiology and Infection Volume 4, Pages S9-S14 (March 1998) DOI: 10.1111/j.1469-0691.1998.tb00683.x Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 The structure of grepafloxacin, a water-soluble fluorinated quinolone. Clinical Microbiology and Infection 1998 4, S9-S14DOI: (10.1111/j.1469-0691.1998.tb00683.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Cumulative susceptibility of Streptococcus pneumoniae to quinolones. Adapted from Fuchs et al [7]. Clinical Microbiology and Infection 1998 4, S9-S14DOI: (10.1111/j.1469-0691.1998.tb00683.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Effect of grepafloxacin and other quinolones in a murine model of pneumonia caused by Streptococcus pneumoniae (n= 6 in each group). Based on Wakebe H. et al [22]. Clinical Microbiology and Infection 1998 4, S9-S14DOI: (10.1111/j.1469-0691.1998.tb00683.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Activity of grepafloxacin and other quinolones in a neutropenic rat lung infection induced by Haemophilus influenzae. Based on Ohmori et al [23]. Clinical Microbiology and Infection 1998 4, S9-S14DOI: (10.1111/j.1469-0691.1998.tb00683.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 5 Comparison of mean steady-state plasma levels of grepafloxacin, 400- and 600-mg doses, in male volunteers with MIC90 values of pathogens of interest. Based on Efthymiopoulos et al [24]. Clinical Microbiology and Infection 1998 4, S9-S14DOI: (10.1111/j.1469-0691.1998.tb00683.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions